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Objective. This study examined the chronic effects of aripiprazole and cariprazine on serotonin (5-HT1A and 5-HT2A)
and glutamate (NMDA and AMPA) receptor subtypes. In addition, the effects of aripiprazole on D2 and D3 receptors
were tested and compared with previously reported cariprazine data.
Methods. Rats received vehicle, aripiprazole (2, 5, or 15mg/kg), or cariprazine (0.06, 0.2, or 0.6mg/kg) for 28 days.
Receptor levels were quantified using autoradiographic assays on brain sections from the medial prefrontal cortex (MPC),
dorsolateral frontal cortex (DFC), nucleus accumbens (NAc), caudate-putamen medial (CPu–M), caudate-putamen lateral
(CPu–L), hippocampal CA1 (HIPP–CA1) and CA3 (HIPP–CA3) regions, and the entorhinal cortex (EC).
Results. Similar to previous findings with cariprazine, aripiprazole upregulated D2 receptor levels in various regions; D3
receptor changes were less than those reported with cariprazine. All aripiprazole doses and higher cariprazine doses
increased 5-HT1A receptors in theMPC andDFC. Higher aripiprazole and all cariprazine doses increased 5-HT1A receptors
in HIPP–CA1 and HIPP–CA3. Aripiprazole decreased 5-HT2A receptors in the MPC, DFC, HIPP–CA1, and
HIPP–CA3 regions. Both compounds decreased NMDA receptors and increased AMPA receptors in select brain regions.
Conclusions. Long-term administration of aripiprazole and cariprazine had similar effects on 5-HT1A, NMDA, and
AMPA receptors. However, cariprazine more profoundly increased D3 receptors while aripiprazole selectively reduced
5-HT2A receptors. These results suggest that the unique actions of cariprazine on dopamine D3 receptors, combined
with its effects on serotonin and glutamate receptor subtypes, may confer the clinical benefits, safety, and tolerability of
this novel compound in schizophrenia and bipolar mania.
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Clinical Implications:
▪ Dysfunctions of the dopamine, serotonin, and gluta-
mate systems contribute to the development and
pathophysiology of schizophrenia and bipolar mania.
▪ Most clinically effective atypical antipsychotics are
known to interact with the serotonin system, modulate
the glutamate system, and induce region-specific
changes in serotonin and glutamate receptor levels.
▪ Aripiprazole, a dopamine D2/D3 receptor partial
agonist, was evaluated for its long-term effects on
dopamine, serotonin, and glutamate receptor levels in
comparison to cariprazine, a potent dopamine D2/D3
receptor partial agonist with preferential binding for
the D3 receptors, in rat forebrain regions.
▪ Aripiprazole produced less-pronounced increases in
D3 receptors as compared to those previously reported
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for another dopamine D2/D3 receptor partial agonist,
cariprazine. Aripiprazole and cariprazine treatment
induced similar changes in 5-HT1A, NMDA, and
AMPA receptors in different rat forebrain regions,
which suggests that these receptors constitute com-
mon targets that mediate the actions of both drugs.
▪ Similar to other atypical antipsychotic drugs, aripi-
prazole treatment induced significant decreases in
cortical 5-HT2A receptors. In contrast, cariprazine
failed to downregulate serotonin 5-HT2A receptors,
which may suggest a minimal role for this receptor in
mediating the actions of cariprazine.
▪ Cariprazine’s unique effects on dopamine and serotonin
receptor subtypes, as well as its shared effects on
glutamate receptor subtypes, may contribute to the
improved clinical benefits of this novel atypical
antipsychotic drug in the treatment of schizophrenia
and bipolar mania.
Introduction
Dysfunctions in dopaminergic, serotonergic, and gluta-
matergic neurotransmissions are believed to play an
important role in the pathophysiology and symptomato-
logy of schizophrenia and other idiopathic psychotic
disorders.1–4 In addition to their effects at dopamine
receptor subtypes, atypical antipsychotics modulate
serotonergic and glutamatergic neurotransmission,
which may contribute to their clinical efficacy, safety,
and tolerability.1,5,6
The atypical antipsychotics cariprazine and aripiprazole
are both dopamine D2/D3 receptor partial agonists;
however, the drugs differ in that cariprazine is D3
receptor-preferring and has moderate affinity for serotonin
5-HT1A receptors.7 Moreover, cariprazine, but not aripi-
prazole, demonstrated high and balanced occupancy of
both D2 and D3 receptors at pharmacologically effective
and antipsychotic doses in both animals8 and schizophrenia
patients.9 In animal behavioral models, cariprazine showed
procognitive10 and antidepressant-like effects,11 suggesting
the potential benefits of cariprazine for both the cognitive
deficits and depressive symptoms of schizophrenia. These
effects of cariprazine are likely to be mediated by D3
receptors, since they were absent in transgenic knockout
mice that lack expression of functional D3 receptors.12,13
We recently reported that long-term treatment with
cariprazine increased D2 and D3 receptor levels in selected
rat forebrain regions, whereas other typical and atypical
antipsychotics upregulated D2 receptors with no effects on
D3 receptors.14 In the present study, we quantified the
long-term effects of aripiprazole on D2 and D3 receptors
and compared them to findings previously obtained for
cariprazine and other antipsychotics.
Previous studies in rats have shown that long-term
treatments with the atypical antipsychotics olanzapine,
risperidone, quetiapine, and asenapine increased ser-
otonin 5-HT1A receptor levels in the medial prefrontal
cortex (MPC) and dorsolateral frontal cortex (DFC)
while decreasing 5-HT2A receptor levels in the same
regions.15,16 Additionally, antipsychotic exposure altered
the levels of ionotropic glutamate N-methyl-D-aspartic
acid (NMDA) and α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) receptors in the caudate
putamen, nucleus accumbens, and hippocampus.17–19
However, all of the tested atypical antipsychotics
displayed combined dopamine D2/serotonin 5-HT2A
receptor antagonism, which is a common feature of
atypical antipsychotic drugs.1,5 The chronic effects of
D2/D3 receptor partial agonists on serotonin and
glutamate receptors require further investigation.
Accordingly, we investigated the effects of long-term
aripiprazole and cariprazine treatment on serotonin (5-
HT1A and 5-HT2A) and glutamate (NMDA and AMPA)
receptor subtypes in the rat forebrain.
Methods
Materials
Tritium autoradiography standards and [2,3-3H]R(+ )-
8-hydroxy-N,N-di-n-propyl-2-amino-1,2,3,4-tetrahydro-
naphthalene ([3H]8-OH-DPAT; 135 Ci/mmol),
[3H]3-[2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl]quina-
zoline-2,4(1H,3H)-dione ([3H]ketanserin; 50 Ci/mmol),
[3H]( + )-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclo-
hepten-5,10-imine ([3H]MK801; 23 Ci/mmol), and
[3H]2-amino-3-(3-hydroxy-5-methyl-isoxazol-4-yl)propa-
noic acid ([3H]AMPA; 58 Ci/mmol) were obtained from
Amersham Life Science (Arlington Heights, IL, USA).
Kodak Biomax MR film was purchased from Thermo
Fisher Scientific (Waltham, MA, USA). D-19 photo-
graphic developer and fixative were obtained from
Eastman Kodak (Rochester, NY, USA).
Aripiprazole HCl and cariprazine HCl were donated
by Forest Laboratories, Inc. (New York, NY, USA).
Pargyline HCl, ketamine, 7-nitro-2,3-dioxo-1,4-dihydro-
quinoxaline-6-carbonitrile (CNQX), ketanserin tartrate,
prazosin, tetrabenzaine, serotonin (5-HT), methyser-
gide, L-glutamate, glycine, and spermine were obtained
from Sigma Research Biochemicals International
(Natick, MA, USA). Cation hydrochlorides, guanosine-
5′-triphosphate sodium (GTP), and tris-(hydroxymethyl)-
aminomethane-HCl (Tris) were obtained from Sigma
Chemicals (St. Louis, MO, USA).
Animals
Male Sprague-Dawley rats (Charles River Laboratories,
Wilmington,MA, USA), initially weighing 200–225g, were
maintained under controlled artificial daylight (7:00 AM–
7:00 PM), temperature, and humidity, with free access
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to standard food and tap water in a USDA-inspected,
veterinarian-supervised, small-animal research facility of
the Mailman Research Center, with approval by the
Institutional Animal Care and Use Committee (IACUC) of
McLean Hospital.
Treatment and tissue preparation
For 28 days, 7 groups of rats (8 animals/group) received
a daily intraperitoneal injection of vehicle control
(distilled water, 1ml/kg) or active treatment of aripipra-
zole (2, 5, or 15mg/kg) or cariprazine (0.06, 0.20, or
0.60mg/kg). The selected doses were active in different
behavioral paradigms.8,20 No gross effects on motor
behaviors or significant changes in body weight were
observed after repeated treatment with the different
doses of aripiprazole or cariprazine compared with
vehicle-treated animals.
At the end of the treatment period, rats were
decapitated 24 hours after the last injection; their brains
were quickly removed, frozen in chilled isopentane, and
stored at –80°C. Brain regions assessed included the
medial prefrontal cerebral cortex (mPFC), dorsolateral
frontal cortex (DFC) (3.2–4.2mm anterior to bregma),
nucleus accumbens (NAc) (1.7–2.2mm anterior to
bregma), medial caudate putamen (CP–M) and lateral
caudate putamen (CP–L) (0.7–1.2mm anterior to
bregma), hippocampus (HIPP), and entorhinal cortex
(0.2–0.7mm anterior to bregma).21 The selected extra-
pyramidal, limbic, and cortical regions of interest
mediate the cognitive, emotional, and motor behaviors
that are typically disturbed in patients with schizophre-
nia and other psychotic disorders.1
Receptor autoradiography and image analysis
Coronal sections (10 μm) of these samples were cut in a
cryostat at –20°C, mounted on gelatin-coated micro-
scope slides, and stored at –80°C. To minimize experi-
mental variability, brain sections from all vehicle- and
drug-treated animals used for a given receptor subtype
assay were evaluated at the same time.
Dopamine receptor autoradiography
For the D2 and D3 assays, sections were first preincu-
bated for 1 h at room temperature (RT). We have
previously shown that this preincubation step is effective
in minimizing the effects of endogenous ligands and the
potential interference of residual drugs.22
D2 receptor binding
Sections were first preincubated for 1 h at RT in 50mM
Tris-HCl buffer (pH 7.4) containing 120mMNaCl, 5mM
KCl, 2mM CaCl2, and 1mM MgCl2. Sections were
incubated for 1 h at RT in the same buffer containing
1.0nM [3H]nemonapride with 0.5µM DTG and 0.1µM
pindolol to mask sigma (σ1,2) and 5-HT1A sites,
respectively. Nonspecific binding (NSB) was determined
with 10 µM S(–)-sulpiride. After incubation, slides
were washed twice for 5min in ice-cold buffer, dipped in
cold water, and air-dried. Radiolabeled slides and [3H]
standards were exposed to Hyperfilm for 4 weeks at
4°C.23,24
D3 receptor binding
Sections were preincubated for 1 h in 50mM Tris-HCl
buffer (pH 7.4) containing 0.3mMGTP and 40mMNaCl
(no MgCl2 added) to minimize labeling of the high-
affinity agonist binding state of D2 receptors, and then
incubated for 1 h in the same buffer containing 3 nM
[3H]7-OH-DPAT, with 5 µM DTG to mask sigma sites.
NSB was determined with 1 µM S(–)-eticlopride. After
incubation, slides were washed (2 ×3min) in ice-cold
buffer and dried. Radiolabeled slides and [3H] standards
were exposed to Hyperfilm for 6 weeks at 4°C.23,24
Serotonin receptor autoradiography
5-HT1A receptor binding
Sections were preincubated for 1 h at RT in 50mM
Tris-HCl buffer (pH 7.6) containing ascorbic acid (0.1%,
w/v), CaCl2 (4mM), and the monoamine oxidase
inhibitor pargyline-HCl (10 μM). Sections were then
incubated for another 60min at RT in fresh buffer
containing 2.0 nM [3H]8-OH-DPAT. NSB was deter-
mined with 1 μM 5-HT. After incubation, slides were
washed (2 × 5min) in ice-cold buffer and air-dried.
Radiolabeled slides and [3H] standards were exposed to
Hyperfilm for 5 weeks at 4°C.15
5-HT2A receptor binding
Sections were preincubated for 60min at RT in 50mM
Tris-HCl buffer (pH 7.7), and then incubated for 1 h at
RT in fresh buffer containing 3.0 nM [3H]ketanserin,
1 μM prazosin (to block α1-adrenoceptors), and 100 nM
tetrabenazine (to block monoaminergic nerve terminal
sites). NSB was determined with 1 μM methysergide.
After incubation, slides were washed (2 × 30min) in
ice-cold buffer, dipped in cold water, and air-dried.
Radiolabeled slides and calibrated [3H] standards were
exposed to Hyperfilm for 5 weeks at 4°C.15
Glutamate receptor autoradiography
NMDA receptor binding
Sections were preincubated for 60min in 50mM
Tris-HCl buffer (pH 7.4) to remove endogenous ligand
and then incubated for 150min at RT in buffer containing
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10nM [3H]MK-801, 100μM L-glutamate, 100μM glycine,
1mM EDTA, and 75μM spermine to enhance the binding
of [3H]MK-801 to NMDA receptors. NSB was determined
with 20μMketamine. After incubation, slides were washed
in ice-cold buffer (2 ×20min) and then air-dried. Radi-
olabeled slides and calibrated [3H] standards were exposed
to Hyperfilm for 4 weeks at 4°C.17,18
AMPA receptor binding
Sections were preincubated for 60min in 50mM Tris-
HCl buffer (pH 7.3) at 4°C and then incubated in fresh
buffer containing 20nM [3H]AMPA for 60min at 4°C.18
NSB was determined with 20μM unlabeled CNQX. After
incubation, slides were washed (3×15 sec) in ice-cold
buffer and air-dried. Radiolabeled slides and [3H] stan-
dards were exposed to Hyperfilm for 3 weeks at 4°C.17,18
Image analysis
Biomax MR films were developed and fixed in Kodak
D-19 for 5min at RT; images were quantified using an
MCID image analyzer and MCID–M4 Imaging Research
software (St. Catharines, Ontario, Canada). A calibration
curve was generated from [3H]-microscale standards that
were exposed along with tissue sections. Regions of
interest were outlined and their optical density mea-
sured, with the left and right sides of two contiguous
sections representing total binding and matching sam-
ples representing nonspecific binding. Four determina-
tions were averaged for each subject sample. Optical
density of sampled regions was measured, and the
amount of ligand bound was calculated as nCi/mg tissue
and expressed as fmol bound/mg tissue.
Statistical analysis
Receptor binding data were analyzed first for overall effects
of drug versus vehicle for all receptor types and brain
regions using multiple regression modeling methods.
Density measures were logarithmically transformed to
achieve more Gaussian-like distributions before regression
modeling. Model goodness-of-fit was checked using partial
residual plot methods. Since individual brain specimens
provided receptor-binding data for several brain regions,
resulting in incomplete independence across observations,
we used robust standard error estimates to adjust for this
clustering effect. This estimation method permits relaxa-
tion of the assumption of independence of all observations
and requires only that the observations be independent
across specimens.25 Estimates of interaction effects were
employed for post-hoc tests of drug effects for specific
receptors and brain regions, with adjustment of p values
obtained from the regression analyses estimating these
multiple comparisons by the standard method of Sidák.26
Data are presented as means ± standard error of the mean
(SEM). Comparisons were considered significant at
p<0.05 (two-tailed test).
Results
Long-term effects of aripiprazole on dopamine receptors
Aripiprazole increased D2 receptor levels in mPFC
(29–48%). However, only the high dose of aripiprazole
(15mg/kg) increased D2 receptors in NAc (40%), medial
(35%), and lateral (50%) CPu, and HIPP (57%)
(Table 1). Chronic aripiprazole treatment (5 and
15mg/kg) significantly increased D3 receptors in the
olfactory tubercle (OT) (15–37%) and Islands of Calleja
(IC) (18–41%) (Table 1). However, aripiprazole, unlike
cariprazine, did not alter the levels of D3 receptors in the
shell of the NAc at any of the doses tested (Table 1).
Long-term effects of aripiprazole and cariprazine on
5-HT1A receptors
Aripiprazole (2, 5, or 15mg/kg) treatment dose-
dependently increased 5-HT1A receptors in the MPC
(24–59%) and DFC (20–39%). Higher doses of aripipra-
zole (5 and 15mg/kg) also increased 5-HT1A receptors in
the HIPP–CA1 (31 and 56%) and HIPP–CA3 (30 and
50%) regions (Table 1, Figure 1A). Similar to aripipra-
zole, cariprazine (0.06, 0.2, or 0.6mg/kg) treatment
dose-dependently increased 5-HT1A receptor binding in
the hippocampal CA1 (33, 42, and 50%, respectively)
and CA3 (29, 39, and 52%, respectively) regions. In
addition, repeated treatment with higher doses of
cariprazine (0.2 and 0.6mg/kg) increased 5-HT1A
receptors in the MPC (41 and 61%) and DFC (42 and
61%) (Table 1, Figure 1B).
Long-term effects of aripiprazole and cariprazine on
5-HT2A receptors
Aripiprazole (2, 5, or 15mg/kg) decreased 5-HT2A
receptors in the MPC (33, 36, and 42%, respectively)
and DFC (32, 39, and 43%, respectively). Aripiprazole
(5 and 15mg/kg) also decreased 5-HT2A receptors in the
HIPP–CA1 (28 and 32%) and HIPP–CA3 (26 and 30%)
regions (Table 1, Figure 2A). In contrast, long-term
administration of cariprazine (0.06, 0.2, and 0.6mg/kg)
failed to alter 5-HT2A receptor levels in all forebrain
regions examined (Table 1, Figure 2B).
Long-term effects of aripiprazole and cariprazine on
NMDA receptors
Long-term administration of higher doses of aripiprazole
(5 and 15mg/kg) decreased NMDA receptors in the
NAc (26 and 30%), CP–M (29 and 31%), and CP–L (30
and 32%) regions. Aripiprazole also dose-dependently
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decreased NMDA receptors in the HIPP–CA1 (18, 27,
and 33%) and HIPP–CA3 (20, 25, and 34%) regions
(Table 1, Figure 3A). Similarly, long-term administration
of higher doses of cariprazine (0.2 and 0.6mg/kg)
significantly reduced NMDA receptor binding in the
NAc (37 and 40%), CP–M (34 and 38%), and CP–L (35
and 38%) regions. In addition, repeated treatment with
0.2 and 0.6mg/kg cariprazine decreased NMDA recep-
tor binding in hippocampal CA1 (25 and 28%) and CA3
(23 and 30%) (Table 1, Figure 3B).
TABLE 1. Changes in forebrain receptors following long-term exposure to cariprazine and aripiprazole
% Control
Cariprazine Aripiprazole
Brain region 0.06 mg/kg 0.2 mg/kg 0.6 mg/kg 2 mg/kg 5 mg/kg 15 mg/kg
Serotonin receptor subtypes 5-HT1A
Cerebral cortex
Medial prefrontal – +41* +61* +25* +57* +59*
Dorsolateral – +42* +61* +20* +34* +40*
Hippocampus
CA1 +33* +42* +50* – +32* +57*
CA3 +29* +39* +52* – +30* +50*
Entorhinal cortex – – – – +29* +57*
5-HT2A
Cerebral cortex
Medial prefrontal – – – –33* –36* –42*
Dorsolateral – – – –32* –39* –43*
Hippocampus
CA1 – – – – –29* –32*
CA3 – – – – –26* –30*
Glutamate Receptor Subtypes NMDA
Cerebral cortex
Medial prefrontal – – – – – –
Dorsolateral – – – – – –
Nucleus accumbens – –37* –40* – –25* –30*
Caudate putamen
Medial – –34* –38* – –29* –30*
Lateral – –35* –38* – –30* –32*
Hippocampus
CA1 – –25* –28* –18* –27* –33*
CA3 – –23* –30* –20* –26* –34*
AMPA
Cerebral cortex
Medial prefrontal – – – – – –
Dorsolateral – – – – – –
Hippocampus
CA1 – +31* +47* – +45* +75*
CA3 – +34* +50* – – +79*
Dopamine Receptor Subtypes D2
a
Cerebral cortex
Medial prefrontal – +27* +43* – +29* +48*
Nucleus accumbens – +40* +45* – – +40*
Caudate putamen
Medial – +41* +53* – – +35*
Lateral – +52* +63* – – +50*
Hippocampus – – +38* – – +57*
D3
a
Islands of Calleja +32* +41* +57* – +18* +41*
Olfactory tubercle +27* +49* +67* – +15* +37*
Nucleus accumbens
Shell – +31* +48* – – –
*p< 0.05 versus respective control; – = not significantly different from respective control.
a Cariprazine data are reproduced from Choi et al.27
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Long-term effects of aripiprazole and cariprazine on
AMPA receptors
Aripiprazole at 5 and 15mg/kg increased [3H]AMPA in
the NAc (26 and 30%), CP–M (29 and 31%), and CP–L
(30 and 32%) regions. Aripiprazole also dose-
dependently increased AMPA receptors in the HIPP–
CA1 (18, 27, and 33%) and HIPP–CA3 (20, 25, and 34%)
regions (Table 1, Figure 4A). Repeated treatment with
the higher doses of cariprazine (0.2 and 0.6mg/kg) dose-
dependently increased [3H]AMPA binding in the
HIPP–CA1 (31 and 47%) and HIPP–CA3 (34 and 50%)
regions. Cariprazine treatment did not alter AMPA receptors
in the other brain regions examined (Table 1, Figure 4B).
Discussion
Long-term effects of aripiprazole and cariprazine on
dopamine D2/D3 receptors
Chronic aripiprazole treatment upregulated D2 receptor
levels in different brain regions, with a maximum
increase similar to that previously described for caripra-
zine and other antipyschotics (Table 1; Choi et al.27).
However, aripiprazole was at least 25-fold less potent
than cariprazine (Table 1; Choi et al.27). Aripiprazole
also increased D3 receptor levels in selective brain
regions; however, these effects were less pronounced
(cariprazine had ~80-fold or greater potency for
D3 receptors) and were produced in fewer brain regions
FIGURE 1. Long-term effects of cariprazine and aripiprazole on serotonin 5-HT1A receptors. Data are mean± SEM (n = 8/group). * p< 0.05 vs. control. CP–L
indicates caudate putamen–lateral; CP–M = caudate putamen–medial; DFC = dorsolateral frontal cortex; EC = entorhinal cortex; HIPP = hippocampus;
MPC = medial prefrontal cortex; NAc = nucleus accumbens.
FIGURE 2. Long-term effects of cariprazine and aripiprazole on serotonin 5-HT2A receptors. Data are mean± SEM (n = 8/group). * p< 0.05 vs. control. CP–L
indicates caudate putamen–lateral; CP–M = caudate putamen–medial; DFC = dorsolateral frontal cortex; EC = entorhinal cortex; HIPP = hippocampus;
MPC = medial prefrontal cortex; NAc = nucleus accumbens.
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than previously described for cariprazine (Table 1;
Choi et al.27). In particular, aripiprazole produced no
effect at any dose tested on D3 receptors in the shell of
the NAc, whereas cariprazine significantly increased
these receptors in the same brain region. Increases in
D3 receptor expression in the shell of the NAc has been
proposed to be a common neurobiological mechanism of
antidepressant treatments.28 These findings suggest that
cariprazine is more potent than aripiprazole in upregu-
lating D3 receptor subtypes, and that D3 receptors play a
more prominent role in mediating the actions of
cariprazine compared to aripiprazole. Moreover, the
unique upregulation of dopamine D3 receptors in areas
related to antidepressant action may offer therapeutic
benefits against various mood disorders, including
depression and the negative symptoms of schizophrenia.
Long-term effects of aripiprazole and cariprazine on
serotonin 5-HT1A receptors
Repeated treatment with the three doses of aripiprazole
(2, 5, and 15mg/kg) and higher doses of cariprazine (0.2
and 0.6mg/kg) dose-dependently increased the binding
of the 5-HT1A radioligand [3H]8-OH-DPAT in MPC and
DFC (Table 1, Figure 1A). This finding is consistent with
the effects of the atypical antipsychotics olanzapine,
risperidone, quetiapine, and asenapine on the same
receptor in the same brain region.15,16,29 Both aripipra-
zole and cariprazine have substantial affinity for 5-HT1A
receptors (Ki = 5.6 and 2.6 nM, respectively) and display
partial agonist activity against this receptor subtype.7,30
Observed increases in cortical 5-HT1A receptors by both
drugs may reflect direct blockade of 5-HT1A receptors or
FIGURE 3. Long-term effects of cariprazine and aripiprazole on NMDA receptors. Data are mean± SEM (n = 8/group). * p< 0.05 vs. control. CP–L indicates
caudate putamen–lateral; CP–M = caudate putamen–medial; DFC = dorsolateral frontal cortex; EC = entorhinal cortex; HIPP = hippocampus; MPC = medial
prefrontal cortex; NAc = nucleus accumbens.
FIGURE 4. Long-term effects of cariprazine and aripiprazole on AMPA receptors. Data are mean± SEM (n = 8/group). * p< 0.05 vs. control. CP–L indicates
caudate putamen–lateral; CP–M = caudate putamen–medial; DFC = dorsolateral frontal cortex; EC = entorhinal cortex; HIPP = hippocampus; MPC = medial
prefrontal cortex; NAc = nucleus accumbens.
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secondary changes resulting from more potent effects on
dopamine D2 and D3 receptors.7,14,30
Earlier studies reported that 5-HT1A receptors are
more highly expressed in cortical and limbic brain
regions than in the basal ganglia.31,32 In the frontal
cortex, 5-HT1A receptors are located on neocortical
glutamatergic pyramidal neurons that are typically
implicated in different cognitive functions.33 Additional
studies have suggested that 5-HT1A partial agonism can
stimulate cortical dopamine release34–36 and minimize
the incidence of antipsychotic-induced extrapyramidal
side effects.37,38 5-HT1A receptors have increasingly
become attractive targets for novel agents to treat
schizophrenia and other psychiatric disorders.39,40
Aripiprazole- and cariprazine-induced increases in cor-
tical 5-HT1A receptors further validate the hypothesis
that the 5-HT1A receptor may contribute, at least in part,
to the beneficial therapeutic effects of these two agents
as well as other dissimilar atypical antipsychotic drugs.15
Repeated administration of aripiprazole (5 and
15mg/kg) and cariprazine (0.06, 0.2 or 0.6mg/kg)
dose-dependently increased binding of the 5-HT1A
radioligand [3H]8-OH-DPAT in hippocampal CA1 and
CA3 regions. Asenapine is the only atypical antipsychotic
that shares this effect, as other atypical antipsychotics,
including olanzapine, risperidone, and quetiapine, did
not alter 5-HT1A receptors in rat hippocampus.15,16
These findings suggest that aripiprazole and cariprazine
can influence hippocampal 5-HT1A receptors and con-
sequently normalize the increased hippocampal activity
postulated to occur in schizophrenic patients and
ameliorate the psychotic symptoms of the disease.41
Long-term effects of aripiprazole and cariprazine on
serotonin 5-HT2A receptors
Long-term treatment with all three aripiprazole doses
significantly and equipotently decreased 5-HT2A recep-
tor binding in the MPC and DFC regions. Aripiprazole
has high affinity for 5-HT2A receptors (Ki = 8.7 nM),30
and the decrease in 5-HT2A binding may reflect direct
blockade of 5-HT2A receptors by the different doses of
aripiprazole. We have previously reported that long-term
administration of several atypical antipsychotics—includ-
ing clozapine, olanzapine, risperidone, quetiapine, and
asenapine—but not the typical antipsychotic haloperidol,
resulted in decreased 5-HT2A receptor labeling in rat
frontal cerebral cortex.15,22,42,43 5-HT2A receptor down-
regulation may minimize the higher incidence of extra-
pyramidal side effects associated with typical antipsychotic
drug treatment.1,44,45 Aripiprazole (5 and 15mg/kg) also
decreased 5-HT2A receptors in the hippocampal CA1 and
CA3 regions. Such downregulation may further contribute
to the stabilization of dopamine neurotransmission in the
limbic system and, consequently, to the improvement of
affective and emotional behaviors typically disturbed in
schizophrenia patients.1
In contrast, cariprazine failed to alter 5-HT2A receptor
binding in all the forebrain regions examined. The lack of
effect of cariprazine on 5-HT2A receptors may result from
its lower in vitro affinity to these receptors, resulting in
insufficient occupancy of 5-HT2A receptors to the level
required to induce receptor changes. These findings
suggest that unlike several of the atypical antipsychotics,
which downregulate cortical 5-HT2A receptors,15,22,42,43
5-HT2A receptors are less likely to contribute to the
mechanism of action of cariprazine in vivo.
Long-term effects of aripiprazole and cariprazine on
glutamate NMDA receptors
Continuous treatment with the higher doses of aripipra-
zole (5 and 15mg/kg) and cariprazine (0.2 and 0.6mg/kg)
significantly decreased binding of [3H]MK-801 to NMDA
receptors in theNAc and themedial and lateral CPu. These
effects were similar to those previously reported for the
atypical antipsychotics clozapine, olanzapine, risperidone,
and asenapine, and the experimental atypical antipsychotic
JL13, but not the typical agent haloperidol.17–19,46
Aripiprazole- and cariprazine-induced reductions in stria-
tal NMDA receptors may result from indirect interactions
with dopamine and serotonin systems, both of which
modulate glutamatergic neurotransmission.47,48 Such
reductions in striatal NMDA receptors may reflect post-
transcriptional modifications, since dissimilar atypical
antipsychotics did not alter expression of mRNA-encoding
NMDA-forming subunits in rat striatum.49,50
We have demonstrated previously that acute and
subchronic administration of cariprazine, as well as
other atypical antipsychotics, reverses both NMDA
receptor antagonist-mediated hypermobility8 and PCP-
induced cognitive and social deficits in animal
models,10,12,51 indicating an ability to normalize abnor-
mal glutamatergic transmission; however, the potential
neurochemical and behavioral consequences of long-
term aripiprazole- and cariprazine-induced reductions in
striatal NMDA receptors are not clear. Studies reported
that stimulation of NMDA receptors promoted typical
antipsychotic-induced catalepsy, an animal model pre-
dictive of extrapyramidal side effects.52 In contrast,
blockade of NMDA receptors attenuated the cataleptic
effects of typical antipsychotic drugs.53 Downregulation
of striatal NMDA receptors by aripiprazole, cariprazine,
and several dissimilar atypical antipsychotic drugs,18,22
as well as the subsequent modification of glutamate
neurotransmission in the basal ganglia, may contribute,
at least in part, to the benign extrapyramidal profile of
atypical antipsychotic agents.45
Repeated treatment with aripiprazole and cariprazine
reduced NMDA receptor binding in the hippocampal
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CA1 and CA3 regions. These effects are similar to the
observed reduction in hippocampal NMDA receptors
after repeated administration of the atypical anti-
psychotics olanzapine and risperidone.18 Reductions
in hippocampal NMDA receptors may normalize the
abnormalities in glutamatergic neurotransmission pos-
tulated to occur in the hippocampus of schizophrenia
patients,54 and thus subsequently improve their psycho-
tic symptoms.55
Long-term effects of aripiprazole and cariprazine on
glutamate AMPA receptors
The three doses of aripiprazole and the higher doses
of cariprazine (0.2 and 0.6mg/kg) dose-dependently
increased AMPA receptors in the hippocampal CA1 and
CA3 regions. These findings are in agreement with
the atypical antipsychotic asenapine, which induced
increases in hippocampal AMPA receptors.19 Such
increases in AMPA receptors may result from the actions
of both aripiprazole and cariprazine on D2 receptors,
which are coexpressed with AMPA in rat brains.56
Increases in hippocampal AMPA receptors may further
contribute to the improvement of psychotic symptoms in
schizophrenia patients. Interestingly, long-term admin-
istration of aripiprazole and cariprazine produced
opposite effects on NMDA versus AMPA receptors,
suggesting that ionotropic glutamate receptors may
respond differently to repeated treatment with partial
D2/D3 receptor agonists.
Conclusions
Long-term treatment with aripiprazole induced
increases in D3 receptors in OT and IC. In contrast,
repeated treatment with cariprazine produced more
profound increases in D3 receptors in OT and IC, and
extended its effect to induce increases in D3 receptors in
the shell of the NAc. These findings are in agreement
with the potent affinity of cariprazine at D3 receptors,
and provide a distinction in the action mechanisms of
cariprazine versus aripiprazole in selectively targeting
D3 receptors as leading sites that mediate the beneficial
actions of cariprazine.
Repeated treatment with aripiprazole and cariprazine
induced similar changes in 5-HT1A, NMDA, and AMPA
receptors in different rat forebrain regions. In contrast,
aripiprazole downregulated 5-HT2A receptors in the
frontal cortex, an effect not seen with cariprazine.
Accordingly, 5-HT2A receptors may contribute more to
the molecular actions of aripiprazole and less to the
actions of cariprazine. In conclusion, the combined
effects of cariprazine on serotonin and glutamate
receptors, together with its unique actions on dopamine
D3 receptors, may confer the clinical benefits, safety, and
tolerability of cariprazine in improved treatment of
schizophrenia and bipolar mania.
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